Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

Philogen provides corporate update

Dec 1, 2022 | 2022, Press Releases, Scientific

The management team to hold a Webinar on Dec 1, 2022, at 10:00 ET / 15:00 GMT / 16:00 CET (Please find the link for the webinar here). Corporate_Update_Dec 1

28 novembre 2022 – Aggiornamento sul programma di acquisto di azioni proprie

Nov 28, 2022 | 2022, Investors, Press Releases

More details

21 novembre 2022 – Aggiornamento sul programma di acquisto di azioni proprie

Nov 21, 2022 | 2022, Investors, Press Releases

More details

Philogen announces publication in Protein Science on the selection and structural characterization of a novel PD-1 blocking antibody

Nov 18, 2022 | 2022, Press Releases, Scientific

The study describes the development of a novel anti-PD-1 antibody that shows potent blockade of PD-1 with a different recognition mechanism compared to anti-PD-1 antibodies that have recently reached the market.   For more details

14 novembre 2022 – Aggiornamento sul programma di acquisto di azioni proprie

Nov 14, 2022 | 2022, Investors, Press Releases

More details

Philogen announces the publication of a new study in the European Journal of Nuclear Medicine and Molecular Imaging

Nov 11, 2022 | 2022, Press Releases, Scientific

The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs. More details
« Older Entries
Next Entries »

Recent Posts

  • Fighting Cancer, the Italian Chemical Society Award to Dario Neri, CEO of Philogen
  • 18 settembre 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • 11 settembre 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • Philogen kindly invites you to attend a virtual briefing for analysts on 2 October 2023 to discuss Company’s Half Year 2023 Results
  • 04 settembre 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it